Millá A, Sanchiz F, Sada G, Villarrubia V G
Anticancer Res. 1986 Jul-Aug;6(4):865-8.
The results of a prospective randomized study of 46 patients with breast carcinoma are presented. Twenty six patients were treated with AM3 (biological response modifier) associated with adjuvant radiotherapy and chemotherapy. Bone marrow hypoplasia was observed in 26.9% of the patients treated with AM3 compared with a 65% incidence in the control group (P less than 0.05). All patients showed leukopenia in peripheral blood count; however, the nadir of leukocytes was 4,000 leu/mm3 in the test group, compared with 1,900 leu/mm3 in the control group. None of the patients in the AM3 group showed thrombocytopenia, whereas 55% in the control group did. In none of the AM-3-treated cases was it necessary to modify the therapeutic schedule of adjuvant treatment.
本文展示了一项针对46例乳腺癌患者的前瞻性随机研究结果。26例患者接受了AM3（生物反应调节剂）联合辅助放疗和化疗。接受AM3治疗的患者中，26.9%出现骨髓发育不全，而对照组的发生率为65%（P<0.05）。所有患者外周血白细胞计数均出现白细胞减少；然而，试验组白细胞最低点为4000个/立方毫米，而对照组为1900个/立方毫米。AM3组患者均未出现血小板减少，而对照组为55%。接受AM3治疗的病例均无需调整辅助治疗的疗程。
